

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

NCT07505745

Status	RECRUITING
Phase	Phase 2
Sponsor	Hudson Biotech
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (7)

- Age 18 to 65 years at the time of consent.
 - Body mass index (BMI) 27.0 to 40.0 kg/m².
 - Prediabetes documented at screening by any of the following: (a) HbA1c 5.7% to 6.4%; (b) fasting plasma glucose 100 to 125 mg/dL; or (c) 2-hour plasma glucose 140 to 199 mg/dL during a 75 g OGTT.
 - Stable body weight (less than 5% change) for at least 3 months prior to screening.
 - Willingness to maintain stable diet and physical activity patterns during the 12-week treatment period.
- ... and 2 more (see full listing online)

Exclusion (9)

- Diabetes mellitus (e.g., HbA1c 6.5% or higher, fasting plasma glucose 126 mg/dL or higher, or 2-hour glucose 200 mg/dL or higher at screening).
 - Use of glucose-lowering medications (including metformin, GLP-1 receptor agonists, SGLT2 inhibitors) within 3 months prior to screening.
 - History of bariatric surgery or planned weight-loss surgery during the study period.
 - Clinically significant cardiovascular disease within 6 months (e.g., myocardial infarction, stroke, unstable angina) or uncontrolled hypertension.
 - Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², clinically significant hepatic disease, or ALT/AST > 2.5x upper limit of normal at screening.
- ... and 4 more (see full listing online)

Locations (1 total)

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China